| Filed On | Filing |
|---|---|
| 09 Jun 2026 |
Form 3: Mushak Andriy, Chief Financial Officer
No securities owned |
| 03 Oct 2025 |
Form 3: Mira PHARMACEUTICALS, Inc., 10% owner
Holds 3,521,127 shares of Common Stock, no par value |
| 10 Jun 2025 | Form 3: Weichselbaum Alan, Chief Financial Officer |
| 29 Aug 2024 |
Form 3: Yanez Michelle, Chief Financial Officer
Holds 24,391 shares of Common Stock |
| 15 Aug 2024 |
Form 3: Del Giudice Matthew Paul, Director
No securities owned |
| 15 Aug 2024 |
Form 3: Whalen Matthew Pratt, Director
No securities owned |
| 15 Aug 2024 |
Form 3: MacPherson Edward Clouston, Director
No securities owned |
| 15 Aug 2024 |
Form 3: Aminov Erez, Director
Holds 30,000 shares of Common Stock |
| 08 Feb 2024 |
Form 3: Nicholoudis Christos, Director
No securities owned |
| 08 Feb 2024 |
Form 3: Chapman Christopher C Jr, Director
Holds 975,610 shares of Common Stock |
| 08 Feb 2024 |
Form 3: Kroenig Bradley, Director
Holds 48,781 shares of Common Stock |
| 08 Feb 2024 |
Form 3: Tuck Talhia, Director
Holds 48,781 shares of Common Stock |
| 08 Feb 2024 |
Form 3: Fuentes Nathen, Chief Financial Officer
Holds 101,134 shares of Common Stock |
| 08 Feb 2024 |
Form 3: Jerman Michael Allen, Director
No securities owned |
| 08 Feb 2024 |
Form 3: McColl Hugh Iii, Director
Holds 48,781 shares of Common Stock |
| 08 Feb 2024 |
Form 3: Eagle Craig, Director
Holds 487,805 shares of Common Stock |
| 08 Feb 2024 |
Form 3: Bay Shore Trust, 10% owner and 1 other
Holds 24,391 shares of Common Stock |
Loading...
